Meyer, B., Traunmueller, F., Hamwi, A., Hollenstein, U.M., Locker, G.J., Sperr, W.R., Staudinger, T., Thalhammer-Scherrer, R., Burgmann, H. and Thalhammer, F. (2004) Pharmacokinetics of Teicoplanin during Continuous Hemofiltration with a New and a 24-h Used Highly Permeable Membrane: Rationale for Therapeutic Drug Monitoring-Guided Dosage. International Journal of Clinical Pharmacology and Therapeutics, 42, 556-560.
https://doi.org/10.5414/CPP42556

has been cited by the following article:

• TITLE: Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment

  AUTHORS: Ying Wang, Jingyi Zhao, Yinhui Yao, Junhui Hu, Jiuli Hu, Xu Xiao, Yanwu Zhao

  KEYWORDS: Mote Carlo Simulation, Dalbavancin, Hepatic Impairment, Renal Impairment

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.11 No.2, February 28, 2020

  ABSTRACT: Dalbavancin is a novel semi-synthetic glycopeptide antibiotic. In this study, we aimed to optimize the dosage regimen of dalbavancin in patients with hepatic or renal impairment by Mote Carlo simulation. Pharmacokinetic parameters and microbiological data were collected about dalbavancin. 10,000 patients with renal or hepatic impairment analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). We found that all bacterial PTA and CFR were more than 90% for dalbavancin in patients with hepatic or renal impairment, except for Enterococcus faecium. There is no need to adjust the dosage regimen of dalbavancin in patients with hepatic or renal impairment.